

# Antimicrobial resistance: Our future depends on what we do today

**BD is leveraging its extensive global capabilities to meaningfully engage around five key strategies to reduce the burden of drug-resistant infections.**



Our global public health efforts seek to expand access and drive capacity-building through partnerships with leading organizations and governments. We engage in advocacy with governments, funders and health agencies to advance innovations to address the world's leading public health needs, including drug-resistant infections.

We possess important capabilities that are instrumental in containing antimicrobial resistance (AMR). We offer a wide range of medical products, platforms and offerings that can be used to prevent the spread of infection in health-care facilities, such as diagnostic systems to screen, test and diagnose infection, including drug-resistant strains, as well as state-of-the-art surveillance and reporting capabilities to monitor, track and predict AMR outbreaks.

Enabled by our innovative programmes and technologies, BD country teams across the globe are directly engaging with AMR leaders in government, academia, and professional societies to strengthen AMR awareness, health systems capacities and infection prevention and diagnostic practices.

Halting and reversing this massive challenge will require the combined resources and efforts of both public and private sectors. AMR has no single solution, and the challenges cannot be solved without multiple players working collectively on a common AMR agenda. BD will continue to collaborate with global leaders around the world to address this urgent global health concern.



**AMR is a global problem, right here, right now, and threatens every person on Earth.**

**But, together, we can make an impact, now, today.**

Learn more at <https://amr.bd.com/> or scan the QR code:

